Phase 1/2 Trial of LY3884961 for Gaucher Disease Initiated by Prevail Therapeutics
Prevail Therapeutics has launched Phase 1/2 clinical trial for LY3884961 in patients with peripheral manifestations of Gaucher Disease.
Therapeutic Area
Therapeutic area intelligence for Gaucher Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.